

CURRICULUM VITAE

PERSONAL INFORMATION

Name: John Edwin Nestler, MD, FACP

Date & Place of Birth: September 24, 1952; Passaic, New Jersey

Citizenship: United States

Marital Status: Married (Michelle Renée Dumont)

Children: John Alexander (born April 9, 1993)
Matthew Joseph (born February 6, 1995)

Business Address: Division of Endocrinology & Metabolism
Medical College of Virginia
Virginia Commonwealth University
P.O. Box 980111
Richmond, VA 23298-0111
Tel.: 804-828-9695; FAX: 804-828-8389
E-mail: nestler@hsc.vcu.edu

EDUCATION

1975-79 University of Pennsylvania, School of Medicine, Philadelphia, Pennsylvania; M.D.

1971-75 Haverford College, Haverford, Pennsylvania; B.A., Chemistry & German

1968-71 West Morris Regional High School, Chester, New Jersey

1965-68 Ungarisches Realgymnasium, Kastl, West Germany

1957-65 St. Stephen's Parochial School, Passaic, New Jersey

POSTDOCTORAL TRAINING

1985-86 Fellow in Endocrinology (Clinical Associate Physician), Medical College of Virginia/VCU, Richmond, Virginia

1983-85 Fellow in Endocrinology, University of Pennsylvania, Philadelphia, Pennsylvania

1982-83 Chief Medical Resident, Medical College of Virginia, VCU, Richmond, Virginia

1980-82 Resident in Medicine, Medical College of Virginia/VCU, Richmond, Virginia

1979-80 Intern in Medicine, Medical College of Virginia/VCU, Richmond, Virginia

ACADEMIC APPOINTMENTS

2003 -present Vice Chair, Department of Internal Medicine, Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia

1997-present Chair, Division of Endocrinology and Metabolism, Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia

1996-1997 Interim Chairman, Division of Endocrinology and Metabolism, Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia

1995-present Professor of Medicine, Obstetrics & Gynecology (joint appointment), and Pharmacology and Toxicology (joint appointment), Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia

1993-95 Associate Professor of Obstetrics & Gynecology (joint appointment), Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia

1991-95 Associate Professor of Medicine, Medical College of Virginia, Virginia Commonwealth University,

Richmond, Virginia
1989-present Graduate Faculty, Virginia Commonwealth University, Richmond, Virginia
1986-91 Assistant Professor of Medicine, Medical College of Virginia, Virginia Commonwealth University,
Richmond, Virginia
1982-83 Instructor in Medicine, Medical College of Virginia, Richmond, Virginia Commonwealth University,
Virginia

UNIVERSITY APPOINTMENTS

2000-present Program Area Head, Reproductive Health, Interdisciplinary Women's Health Research (IWHR)
Program, Virginia Commonwealth University, Richmond, Virginia
1996-2003 Program Director, Fellowship Program in Endocrinology and Metabolism, Medical College of
Virginia, Virginia Commonwealth University, Richmond, Virginia
1992-1995 Associate UHC/TAC Clinical Trials Liaison, Virginia Commonwealth University, Richmond, Virginia
1991-1995 Director of Medical Affairs, BioClin, Virginia Commonwealth University, Richmond, Virginia

CONSULTANTSHIPS

1997-2001 Consultant, Bristol-Myers Squibb Company, Princeton, New Jersey
1996-2002 Consultant & Member of the Scientific Advisory Committee, INSMED Pharmaceuticals, Inc.,
Richmond, Virginia
1993-1995 Consultant & Member of the Scientific Advisory Committee, Paradigm Biosciences, Inc., Salt Lake
City, Utah

MILITARY SERVICE

None

BOARD CERTIFICATION

Endocrinology and Metabolism (ABIM) (No. 085095), 1985
American Board of Internal Medicine (No. 085095), 1982
National Board of Medical Examiners (No. 193650), 1980

SOCIETIES

Androgen Excess Society
President, 2002-2003
Past President, 2003-2004
American Society for Clinical Investigation
Alpha Omega Alpha
Southern Society for Clinical Investigation
The Endocrine Society
Research Affairs Committee, 2001-2004
Association for Patient-Oriented Research
American Society of Program Directors in Endocrinology and Metabolism
International Study Group for Steroid Hormones
American Federation for Clinical Research
Councilor, Southern Section, 1988-1991
Medical School Representative, 1986-1988
American College of Physicians (Fellow)
Planning Committee, 1990 ACP Virginia Scientific Meeting
Associates Committee, 1983 ACP Virginia Scientific Meeting
American Diabetes Association
President, Virginia Affiliate, 1990-1991
President-Elect, Virginia Affiliate, 1988-1990
Secretary, Virginia Affiliate, 1987-1988
Member, Executive Committee, 1987-1992
Member, Board of Directors, Virginia Affiliate, 1986-1994
Member, Research Committee, Virginia Affiliate, 1987-1991
President, Richmond Chapter, 1988-1989

President-Elect, Richmond Chapter, 1987-1988
Member, Board of Directors, Richmond Chapter, 1986-1992
American Fertility Association
Medical Advisory Board
Polycystic Ovary Syndrome Support Association
Medical Advisory Board
Juvenile Diabetes Foundation International
New York Academy of Sciences
Central Virginia Reproductive Endocrine Society
PCOS Association
Member, Advisory Board, 1997-present
Hungarian Medical Association of America
Worldwide Hungarian Medical Association
The Philadelphia Endocrine Society (1983-1985)

AWARDS AND HONORS

VCU School of Medicine Outstanding Research Achievement Award, 2001-2002
Outstanding Course Certificate Award for Teaching Excellence in MII Endocrine, 2000
Outstanding Investigator Award of the Southern Section AFCM, 1998
Outstanding Research Award of the Department of Internal Medicine at MCV, 1998
Appointed the William G. Blackard Professor of Medicine at Virginia Commonwealth University, 1998-present
Pfizer Visiting Professor, University of Pittsburgh, January 14-16, 1998
Honorary Member, Venezuelan Association of Atherosclerosis, 1995
Honorable Mention, MCV Housestaff's Best Faculty Teacher/Attending Award, 1995
Dr. James H. and Dorothy S. Hutton Traveling Scholar, American College of Physicians, 1993-94
Best Professor Award for M-II Endocrine Course in both 1993 and 1990
Inducted as Fellow in the American College of Physicians, 1989
Clinical Associate Physician (CAP) award from NIH, 1985-1987
Young Investigator Award from the ADA, Virginia Affiliate, 1986
Sandra Tate Russell Memorial Research Award, ADA, Virginia Affiliate, 1986
The Philadelphia Endocrine Society 1985 Research Trainee Award
The Philadelphia Endocrine Society 1984 Research Trainee Award
Graduated from Haverford College with Honors in Chemistry

PATENTS

U.S. Patent #4,920,115: "Method of lowering LDL cholesterol in blood;" John Nestler, Cornelius Barlaschini, John Clore, William Blackard; April 24, 1990

U.S. Patent #5,100,810: "Method of using dehydroepiandrosterone and dehydroepiandrosterone-sulfate as inhibitors of platelet aggregation;" David Eich, Robert Jesse, John Nestler; May 5, 1992

U.S. Patent #5,162,198: "Method of using dehydroepiandrosterone and dehydroepiandrosterone-sulfate as inhibitors of thromboxane production and platelet aggregation;" David Eich, Robert Jesse, John Nestler; November 10, 1992

EDITORIAL BOARDS/JOURNAL REVIEWS

A. Editorial Board

Journal of Women's Health, Section Editor for Endocrinology, 2005-present
Hormones, 2004-present
Journal of Clinical Endocrinology and Metabolism, 2001-2003
Current Opinion in Endocrinology, 2001-2002
Steroids, 1999-2002

B. Reviewer

Acta Endocrinologica (Copenh)

American Journal of Medicine
American Journal of Medical Sciences
American Journal of Obstetrics & Gynecology
American Journal of Physiology
Clinical Endocrinology (Oxf)
Diabetes
Diabetes Care
Diabetologia
Endocrinology
International Journal of Obesity
Journal of Clinical Endocrinology and Metabolism
Journal of Endocrinological Investigation
Lancet
Life Sciences
Metabolism
New England Journal of Medicine
Obesity Research
Obstetrics & Gynecology
Steroids

UNIVERSITY AND DEPARTMENTAL COMMITTEES

A. University

Search Committee for Dean, 2003-2004
Strategic Research Advisory Group, 2001-2003
Executive Committee of the Faculty, 1999-2001
Chair, Internal Review Committee of Physical Medicine & Rehabilitation Residency Program, 2000
Research Subcommittee, Liaison Committee on Medical Education, 1999-present
Member, M.D./Ph.D. Steering Committee, 1997-2000
Coursemaster, M-II Endocrine Course, 1994-1998
Member, Graduate Advisory Committee for Ph.D. candidate in Biostatistics, 1996-present
Ad hoc Member, Departmental Tenure & Promotion Committee for Pharmacology & Toxicology, 1995
Ad hoc Member, Departmental Tenure & Promotion Committee for Obstetrics & Gynecology, 1992 & 1995
Ad hoc Member, Departmental Tenure & Promotion Committee for School of Pharmacy, 1993
Member, Graduate Advisory Committee for Ph.D. candidate in Physiology, 1992-1994
Member, Graduate Advisory Committee for Ph.D. candidate in School of Pharmacy, 1989-90
Faculty Senate, 1987-1988
Adjunct Admissions Committee, Medical School, 1987-1990
Advisory Board, VCU Research in Action, 1987-1990

B. Department

Chair, Search Committee for Associate Chair for Administration
Chair, Search Committee for Chair of Division of Nephrology, 2003-2004
Member, Space Committee, 2000-2002
Chair, Search Committee for Chair of Division of Rheumatology, Allergy and Immunology, 2000
Member, Departmental Tenure & Promotion Committee, 1999
Research Advisory Council, 1997-2002
Faculty Development Committee, 1996-2002
M-III Internal Medicine Core Lectures, 1996-present
Director of Faculty Clinical Assignments, 1995-2002
Chairman, Clinical Competence Committee, Department of Internal Medicine, 1994-1998
Board of Directors, University Internal Medicine Foundation (UIMF), 1992-present
Finance Committee, University Internal Medicine Foundation (UIMF), 1990-present
Clinical Competence Committee, Department of Internal Medicine, 1990-1999
Ad Hoc Committee for Oral Exams, M-III Medicine Clerkship, 1989-2001
Evaluation Committee for Division of Endocrinology & Metabolism, 1988-present
Intern Selection Committee, Department of Internal Medicine, 1985-1999

VISITING PROFESSOR/ENDOCRINE GRAND ROUNDS

University of Toronto, Toronto, Canada; Citywide Endocrine Rounds: "Insulin resistance and PCOS: Clinical implications;" April 29, 2005.

UMDNJ-Robert Wood Johnson Medical Center, Rutgers, NJ; Reproductive Endocrinology Grand Rounds: "PCOS and insulin resistance: implications for treatment of infertility;" February 28, 2005.

Brown University, Providence, RI; Endocrine Grand Rounds: "PCOS and insulin resistance: clinical implications;" November 3, 2004.

Cedars-Sinai Medical Center, Los Angeles, CA; Ob/Gyn Grand Rounds: "PCOS and insulin resistance: role of inositolphosphoglycan mediators;" October 26, 2004.

University of Southern California, Los Angeles, CA; Endocrine Grand Rounds: "PCOS and insulin resistance: clinical implications;" October 25, 2004.

University of Maryland, Baltimore, MD; Endocrine Grand Rounds: "Polycystic ovary syndrome and insulin resistance: the metabolic syndrome;" October 18, 2004.

NICHD/NIH, Bethesda, MD; Endocrine Rounds: "Polycystic ovary syndrome and insulin resistance: implications for the treatment of infertility;" September 14, 2004.

University of Chicago, Chicago, IL; Endocrine Grand Rounds: "Polycystic ovary syndrome: clinical implications;" March 25, 2003.

Visiting Professor; University of Vermont College of Medicine, Burlington, VT; March 13-14, 2003.

NICHD/NIH (Pediatric and Reproductive Endocrinology Branch), Bethesda, MD, Grand Rounds: "Insulin resistance and polycystic ovary syndrome: clinical implications;" May 7, 2002.

University of Rochester, Rochester, NY; Ob/Gyn Grand Rounds: "Insulin and the polycystic ovary syndrome;" March 14, 2002.

Philadelphia Endocrine Society, Philadelphia, PA; "Polycystic ovary syndrome;" January 9, 2002.

Indiana University School of Medicine, Indianapolis, IN; Endocrine Grand Rounds; "The inositolphosphoglycan system: can it explain both the insulin resistance and the hyperandrogenism of the polycystic ovary syndrome?"; May 23, 2001.

University of Virginia, Charlottesville, VA; Endocrine Grand Rounds; "The inositolphosphoglycan system: can it explain both the insulin resistance and the hyperandrogenism of the polycystic ovary syndrome?"; May 1, 2001.

University of Texas Health Sciences Center, San Antonio, TX; Medical Grand Rounds; "Insulin resistance and the polycystic ovary syndrome;" April 4, 2001.

Visiting Professor, Penn State/Milton Hershey Medical Center, Hershey, PA; Molecular Biochemistry and Physiology Research Seminar: "Role of inositolphosphoglycan mediators of insulin action in the polycystic ovary syndrome," and Ob/Gyn Grand Rounds: "Polycystic ovary syndrome: the insulin resistance connection;" November 8-9, 2000.

Southwestern Medical Center, Dallas, TX; Endocrine Grand Rounds: "Diabetes risk factor management: polycystic ovary syndrome and insulin resistance;" October 13, 1999.

Massachusetts General Hospital, Boston, MA; ; Endocrine Grand Rounds: "Polycystic ovary syndrome: the insulin story;" June 28, 1999.

Beth Israel Hospital, Boston, MA; ; Endocrine Grand Rounds: "Polycystic ovary syndrome: the insulin story;" May 28, 1999.

Washington University, St. Louis, MO; Ob/Gyn Grand Rounds: "Insulin resistance and the polycystic ovary syndrome;" May 12, 1999.

Temple University, Philadelphia, PA; Endocrine Grand Rounds: "Polycystic ovary syndrome: the insulin story;" April 10, 1999.

University of Virginia, Charlottesville, VA; Endocrine Grand Rounds: "Polycystic ovary syndrome: the insulin story;" April 6, 1999.

Emory University, Atlanta, GA; Endocrine Grand Rounds: "Polycystic ovary syndrome: the insulin story;" February 10, 1999.

Mount Sinai Medical School, New York, NY; Diabetes Grand Rounds: "Polycystic ovary syndrome: the insulin story;" November 23, 1998.

Walter Reed Medical Center, Bethesda, MD; Ob/Gyn Grand Rounds: "Polycystic ovary syndrome: the insulin story;" November 12, 1998.

University of Alabama, Birmingham, AL; Endocrine Grand Rounds: "Polycystic ovary syndrome: the insulin story;" November 5, 1998.

Johns Hopkins Medical School, Baltimore, MD; Ob/Gyn Grand Rounds: "Polycystic ovary syndrome: the insulin story;" October 15, 1998.

Pfizer Visiting Professor; University of Pittsburgh; January 14-16, 1998.

Louisiana State University, New Orleans, LA; Visiting Professor and Medical Grand Rounds: "Evaluation and treatment of the hirsute woman;" November 16, 1997.

Ochsner Clinic, New Orleans, LA; Medical Grand Rounds: "Insulin and the polycystic ovary syndrome;" November 15, 1997.

University of Pennsylvania, Philadelphia, PA; Grand Rounds for the Center for Research on Reproduction and Women's Health: "Insulin and the polycystic ovary syndrome;" September 10, 1997

National Institutes of Health, Bethesda, MD ; Endocrine Grand Rounds: "Insulin and the polycystic ovary syndrome: clinical and therapeutic implications;" May 30, 1997

University of North Carolina School of Medicine, Chapel Hill, NC; Ob/Gyn Grand Rounds: "Insulin and the polycystic ovary syndrome: clinical and therapeutic implications;" May 21, 1997

Baylor College of Medicine, Huffington Center on Aging, Houston, TX: "Insulin regulation of human DHEA metabolism: a link to atherosclerosis?;" March 27, 1995.

University of Alabama, Birmingham, AL; Endocrine Grand Rounds: "Insulin and the polycystic ovary syndrome;" and Dept. of Ob/Gyn Grand Rounds: "Role of insulin resistance in ovulation disorders;" November 15-17, 1994.

The Jones Institute for Reproductive Medicine, Eastern Virginia Medical School, Norfolk, VA; Research Seminar: "Insulin's role in the polycystic ovary syndrome;" June 10, 1994.

Massachusetts General Hospital, Harvard Medical School, Boston, MA; Endocrine Grand Rounds: "Insulin's role in the polycystic ovary syndrome;" May 24, 1994.

Louisiana State University, New Orleans, LA; Visiting Professor and Endocrine Grand Rounds: "Insulin and DHEA metabolism," and Residents' Rounds: "Treatment of hypertension in diabetes: let's not forget Syndrome X;" May 16-17, 1994.

University of Chicago, Chicago, IL; Endocrine Research Seminar: "Insulin's role in the polycystic ovary syndrome;" May 9, 1994.

Diabetes Institutes, Norfolk, VA; Research Seminar: "Insulin regulation of human androgen metabolism," and "Treatment of hypertension in diabetes: let's not forget Syndrome X;" February 17, 1994.

Semmelweis Medical School, Budapest, Hungary; *Dr. James H. and Dorothy S. Hutton Traveling Scholar* of the American College of Physicians; June 26-July 29, 1993

University of Bologna, Bologna, Italy; Reproductive Endocrinology Grand Rounds: "Insulin's role in the polycystic ovary syndrome;" June 12, 1992.

Dalhousie University, Halifax, Nova Scotia, Canada; Visiting Professor and joint Endocrine & Ob/Gyn Grand Rounds: "Insulin and human androgen metabolism;" May 23, 1991.

INVITED SPEAKER

A. National Scientific Meetings

Reproduction2003, NICHD/NIH: "Insulin resistance and the polycystic ovary syndrome: Implications for reproduction;" Bethesda, MD, November 9, 2003.

Clinical Endocrinology Update 2003, The Endocrine Society, "Insulin resistance and PCOS: Metabolic and Cardiovascular Implications;" Miami, FL, Oct. 26, 2003.

85th Annual Meeting of The Endocrine Society, Endocrine Nurses Society Symposium, "Insulin resistance and the polycystic ovary syndrome;" Philadelphia, PA, June 21, 2003.

58th Annual Meeting of the American Society for Reproductive Medicine, "Debate: Resolved, insulin sensitizers play a major role in the treatment of PCOS: pros and cons," and "Detection and prevention of diabetes and cardiovascular disease in PCOS;" Seattle, WA, October 15-16, 2002.

Insulin Resistance Syndrome Conference of the American College of Endocrinology, "Role of insulin resistance in the polycystic ovary syndrome;" Washington, D.C., August 26, 2002.

84th Annual Meeting of The Endocrine Society, "Insulin resistance and the polycystic ovary syndrome: clinical implications;" San Francisco, CA, June 22, 2002.

62nd Annual Scientific Sessions of the American Diabetes Association, "Insulin resistance and miscarriage: lessons from metformin and polycystic ovary syndrome;" San Francisco, CA, June 17, 2002.

American Society for Reproductive Medicine; Symposium Lecture: "Use of insulin sensitizing drugs in the polycystic ovary syndrome;" Orlando, FL, October 23, 2001.

American Association of Clinical Endocrinologists; Plenary Lecture: "Polycystic ovary syndrome and insulin resistance;" San Antonio, TX, May 4, 2001.

NIH Mid-Atlantic Diabetes Symposium; Plenary Lecture: "Role of inositolphosphoglycans in the insulin resistance of the polycystic ovary syndrome;" Bethesda, MD, October 7, 2000.

Annual Meeting of the American Society of Bariatric Physicians; Title: "Role of insulin resistance in the polycystic ovary syndrome;" Washington, D.C., October 6, 2000.

Annual meeting of the American Association of Diabetes Educators; Title: "Polycystic ovary syndrome – the link to Type 2 diabetes," San Diego, CA, August 9, 2000.

14th Annual Meeting of the American Association of Nurse Practitioners; Title: "Women's health: Insights into the polycystic ovary syndrome;" Atlanta, GA, June 15-19, 1999.

American Diabetes Association 46th Postgraduate Course; Symposium on Insulin Resistance; Title: "Infertility: an insulin resistance problem?"; Orlando, FL, January 22-24, 1999.

80th Annual Meeting of The Endocrine Society; Symposium on Pharmacological Antidotes to Aging; Title "DHEA: fountain of youth or snake oil?"; New Orleans, LA, June 24-27, 1998.

American Association of Clinical Endocrinologists, Symposium on Long-term Prevention of Diabetic Complications; Title: "Polycystic ovary syndrome and insulin resistance," Phoenix, AZ, November 15, 1997

38th Annual Symposium on Advances in Clinical Nutrition (American College of Nutrition); Title: "DHEA and prevention of heart disease," New York, NY, September 28, 1997

75th Annual Meeting of The Endocrine Society; Symposium on Metabolic Aspects of Polycystic Ovary Syndrome; Title: "Central role of insulin in the pathogenesis of the polycystic ovary syndrome," Las Vegas, NV, June 10, 1993

53rd Annual Meeting of the American Diabetes Association; Symposium on Sex Hormones, Insulin Resistance, and Obesity-Associated Diabetes; Title: "DHEA: the link between hyperinsulinemia and macrovascular disease?"; Las Vegas, NV, June 15, 1993

NIH/NICHD Conference on Polycystic Ovary Syndrome; Title: "Insulin action on steroidogenesis in vivo," Bethesda, MD, April 16-18, 1990; also Chairman of "Growth Factors" session

18th Steenbock Symposium on "Hormones, thermogenesis and obesity;" Title: "Dehydroepiandrosterone: effects on insulin sensitivity, serum lipid levels, and body composition in normal men," University of Wisconsin, Madison, WI, June 12-16, 1988

B. International Scientific Meetings

11th World Congress of Gynecological Endocrinology; Title: "Polycystic ovary syndrome and insulin resistance: Implication for treatment of infertility;" Florence, Italy; February 28, 2004.

1st Annual World Congress on the Insulin Resistance Syndrome; Title: Insulin resistance and PCOS: Clinical implications; Los Angeles, CA; November 22, 2003.

PCOS Current Concepts: Treatment & Ovulation Induction; Title: "Should insulin-sensitizing drugs be used in the treatment of PCOS? An enthusiastic endorsement;" Antalya, Turkey, September 5, 2003.

29th Panhellenic Medical Congress; Title: "Insulin resistance and polycystic ovary syndrome: clinical implications;" Athens, Greece, May 23, 2003.

12th Balkan Congress of Endocrinology and 30th Panhellenic Congress of Endocrinology and Metabolism; Title: Insulin resistance and the polycystic ovary syndrome: reproductive, metabolic and cardiovascular implications;" Thessaloniki, Greece, May 21-23, 2003.

20th Annual Scientific Meeting of Association des Médecins Endocrinologues du Québec; Title: Polycystic ovary syndrome and insulin resistance: clinical implications," Aylmer, Canada, May 25, 2002.

NIH International Symposium on Polycystic Ovary Syndrome; Title: "Insulin lowering drugs as investigative tools and therapy in the polycystic ovary syndrome," Research Triangle Park, NC, September 17-20, 2000.

Member of Scientific Advisory Committee & Invited Speaker, Conference on "Endocrine Basis of Reproductive Function;" Title: "Use of Insulin-Sensitizing Drugs in PCOS," Tampa, FL, January 27-29, 2000.

Member of Scientific Advisory Committee & Invited Speaker, Satellite Symposium of the 8th International Congress on Obesity ("Endocrinology of Obesity: Basic, Clinical, and Therapeutic Aspects"); Title: "Insulin and ovarian androgens," Venice, Italy; September 4-6, 1998.

Member of Scientific Advisory Board & Invited Speaker, 4th International Congress of the Worldwide Hungarian Medical Academy; Title: "Insulin resistance and the polycystic ovary syndrome," Budapest, Hungary; August 27-28, 1998.

Member of Scientific Advisory Committee, First International Symposium on the "Developmental Aspects of Androgen Excess"; Title: "Regulation of ovarian P450c17 α activity by insulin," Minneapolis-St. Paul, MN; June 14-15, 1997

1997 World Congress of Gerontology; Title: "Administration of DHEA to humans," Honolulu, Hawaii; August 16-19, 1997

Venezuelan Congress of Gynecology; Title: "Insulin resistance and the polycystic ovary syndrome," Barquisimeto, Venezuela; March 6-10, 1997

IV International Symposium of the Venezuelan Association of Atherosclerosis; Title: "Metabolic roles of dehydroepiandrosterone and insulin in humans, and their relevance to atherosclerosis," Maracaibo, Venezuela, February 8-10, 1996

Satellite Symposium of the 15th Congress of the International Federation of Fertility Societies ("Weight, Nutrition, and Hormonal Events in Women"); Title: "Insulin and androgen excess: what remains essential 10 years later?," Montpellier, France, September 15-16, 1995

New York Academy of Sciences conference on "Dehydroepiandrosterone (DHEA) and Aging;" Title: "Insulin regulation of human DHEA metabolism," Washington, D.C., June 17-18, 1995.

7th International Congress on Obesity; Title: "DHEA, obesity, and obesity-related complications," Toronto, Canada, August 20-25, 1994

XIII Pan-American Congress of Endocrinology; Title: "Insulin resistance: diagnostic strategies and therapeutic possibilities," Santiago, Chile, April 10-14, 1994

Ovulation Induction: Basic Science and Clinical Advances; Title: "Role of obesity and insulin in the development of anovulation," Palm Beach, FL, January 20-22, 1994

International Aromatase Conference III; Title: "Regulation of the aromatase activity of human placental cytotrophoblasts by insulin, IGF-I, and IGF-II," Bologna, Italy, June 14-17, 1992

VIII. International Congress on Hormonal Steroids; Title: "DHEA actions and metabolism in man," The Hague, The Netherlands, September 16-21, 1990

6th International Symposium: "Recent progress in perinatal medicine;" Title: "Insulin and insulin-like growth factor I as modulators of human placental steroidogenesis," Budapest, Hungary, September 28-30, 1989

Symposium Pharmaco-Clinique Roussel Uclaf NE 9: "Dehydroepiandrosterone Revisited;" Title: "Effects of dehydroepiandrosterone (DHEA) in man," Paris, France, January 19-20, 1989

GRANT REVIEWS

Member, NIH Reproductive Endocrinology (REN) Study Section, 2001-2003

Ad hoc member, NIH Reproductive Endocrinology (REN) Study Section, 2001
Ad hoc reviewer, NIH/NHLBI for Special Emphasis Panel, 1999
Ad hoc reviewer, NIH/NIDDK for CIA Award, 1994
Ad hoc reviewer, Medical Research Council of United Kingdom, 1994
NIH Site Visitor for GCRC Program at University of Texas, Galveston, TX, July 16-17, 1992
Ad hoc reviewer, Medical Research Council of Canada, 1990 & 1992
Ad hoc reviewer, Harold Wetterberg Foundation, Roseland, NJ, 1992
Ad hoc reviewer, Veterans Administration Merit Review Board in Endocrinology, 1988

OTHER SCHOLARLY ACTIVITIES

Chair, Scientific Advisory Board to Meharry Medical College's NIH U54 Cooperative Center for Research in Reproduction, 2004-present
External Consultant to the University of Pittsburgh's NIH U54 Reproduction Center, 1998-2003
Co-organizer and co-chairman of conference on "Dehydroepiandrosterone (DHEA) and Aging" sponsored by the New York Academy of Sciences and NIA/NIH, Washington, D.C., June 17-19, 1995
Member, Advisory Committee to NIA/NIH for conference on "The Role of Dehydroepiandrosterone in Aging," Bethesda, MD, November 23, 1992
Co-chairman for Metabolism session at 1990 Southern Section AFCR/SSCI Meeting

GRANTS

Active

NIH R01HD35629

"Insulin and the polycystic ovary syndrome"

John E. Nestler (PI) (40% effort); Direct costs: \$1,627,900; 7/1/97-6/30/05

NIH K24HD40237 Mid-Career Investigator Award

"Polycystic ovary syndrome: role of insulin resistance"

John E. Nestler (PI) (30% effort); Direct costs: \$506,395; 04/01/01-03/31/06

NIH HD-96-008 (U54 Reproduction Center)

"Clinical and basic studies in polycystic ovarian syndrome;" John C. Marshall (PI and Director)

John E. Nestler (PI of subproject "Ovarian/metabolic responses to insulin in PCOS;" 20% effort)

Direct costs of subproject: \$450,757; 4/1/98-3/31/06

Inactive

NIH 1R01CA64500

"Insulin, insulin resistance, and breast cancer"

John E. Nestler (PI) (35% effort); Direct costs: \$443,011; 08/25/95-07/31/00

NIH SBIR R43HD35772

"Role of inositol glycan mediators in the polycystic ovary syndrome"

Geoffrey Allan, CEO, Insmmed Pharmaceuticals (PI)

John E. Nestler (Principal Clinical Investigator) (5% effort)

Direct costs: \$100,000; 7/1/97-12/31/97

NIH 1R01AG11227

"Insulin regulation of human adrenal androgen metabolism"

John E. Nestler (PI); Direct costs: \$226,930; 1/1/93-12/31/97

Juvenile Diabetes Foundation Research Grant

"An examination of insulin's effect on vascular permeability"

John E. Nestler (PI) Direct costs: \$97,460; 9/1/91-2/1/94

A.D. Williams Fund for Research (MCV/VCU intramural grant)
"Effects of insulin on luteinizing hormone (LH) release in obese women with the polycystic ovary syndrome."
John E. Nestler (PI) Direct costs: \$7,500; 12/1/92-11/30/93

Jeffress Trust Research Grant: "Diabetes and pregnancy: an evaluation of the effects of insulin and IGF-I on human placental steroidogenesis"
John E. Nestler (PI) Direct costs: \$48,600; 1/1/90-12/31/92

American Diabetes Association, Virginia Affiliate, Research Grant
"Insulin as an effector of human steroidogenesis."
John E. Nestler (PI) Direct costs: \$50,000; 7/1/89-6/30/91

Diabetes Research & Education Foundation: "An examination of the effect of hyperinsulinemia on vascular permeability in normal men"
John E. Nestler (PI) Direct costs: \$19,600; 1/1/90-12/31/90

Virginia Commonwealth University Grant-in-Aid: "An examination of 6 β -hydroxylase activity of human placental cells and its relationship to toxemia of pregnancy."
John E. Nestler (PI) Direct costs: \$7,000; 1/1/90-12/31/90

American Diabetes Association Feasibility Grant
"Insulin as an effector of human placental steroidogenesis."
John E. Nestler (PI) Direct costs: \$50,000; 7/1/86-6/31/88

Small Grants Award (MCV intramural grant): "Insulin as an effector of human placental steroidogenesis."
John E. Nestler (PI) Direct costs: \$10,000; 6/1/87-3/31/88

A.D. Williams Fund for Research (MCV/VCU intramural grant)
"Effect of insulin on trophoblastic P450 side-chain cleavage enzyme activity."
John E. Nestler (PI) Direct costs: \$7,500; 6/1/86-5/31/87

NIH Clinical Associate Physician award (RR00065): "Role of qualitative and quantitative aspects of insulin release on the insulin resistance following insulin-induced hypoglycemia."
John E. Nestler (PI) Direct costs: \$110,800; 10/1/85-9/30/87

7/85-9/85	National Research Service Award: 5 T32 AM 07428-03
10/84-6/85	National Research Service Award: 1 T32 AM 07481-01
7/83-6/84	National Research Service Award: 2 T32 AM 07314-05

BIBLIOGRAPHY

Original Publications

1. **Nestler JE**: Immunoglobulin D multiple myeloma with thrombocytosis [case report]. Ann Intern Med 94:412, 1981.
2. **Nestler JE**, Stratton MA, Hakim CA: Effect of metoclopramide on diabetic neurogenic bladder. Clin Pharm 2:83-85, 1983.
3. **Nestler JE**: Hemochromatosis and pruritus [case report]. Ann Intern Med 98:1026, 1983.
4. **Nestler JE**, Gebhart SSP, Blackard WG: Failure of a midnocturnal insulin infusion to suppress the increased insulin need for breakfast in insulin-dependent diabetic patients. Diabetes 33:266-270, 1984.
5. **Nestler JE**, Chacko GK, Strauss III JF: Stimulation of rat ovarian cell steroidogenesis by high density lipoproteins modified with tetranitromethane. J Biol Chem 260:7316-7321, 1985.
6. **Nestler JE**, Bamberger M, Rothblat GH, Strauss III JF: Metabolism of high density lipoproteins reconstituted with [3H]cholesteryl ester and [14C]cholesterol in the rat, with special reference to the ovary. Endocrinology 117:502-519, 1985.
7. Paavola LG, Strauss III JF, Boyd CO, **Nestler JE**: Uptake of gold- and [3H]cholesteryl linoleate-labeled human low density lipoprotein by cultured rat granulosa cells: cellular mechanisms involved in lipoprotein metabolism and their importance to steroidogenesis. J Cell Biol 100:1235-1247, 1985.
8. Kliman HJ, **Nestler JE**, Sermasi E, Sanger JM, Strauss III JF: Purification, characterization and *in vitro* differentiation of cytotrophoblasts from human term placentae. Endocrinology 118:1567-1582, 1986.
9. Veldhuis JD, **Nestler JE**, Strauss III JF, Gwynne JT: Insulin regulates low-density lipoprotein binding and degradation by swine granulosa cells. Endocrinology 118:2242-2253, 1986.
10. **Nestler JE**: Stimulation of androgen production by insulin-like growth factor I [case report]. Ann Intern Med 105:796, 1986.
11. **Nestler JE**, Clore JN, Failla ML, Blackard WG: Effects of extreme hyperinsulinaemia on serum trace metals, trace metal binding proteins, and electrolytes in normal females. Acta Endocrinol (Copenh) 114:235-242, 1987.
12. **Nestler JE**, Clore JN, Strauss III JF, Blackard WG: Effects of hyperinsulinemia on serum testosterone, progesterone, dehydroepiandrosterone sulfate, and cortisol levels in normal women and in a woman with hyperandrogenism, insulin resistance and acanthosis nigricans. J Clin Endocrinol Metab 64:180-184, 1987.
13. **Nestler JE**, McLeod JF, Kowalski MA, Strauss III JF, Haddad Jr. JG: Detection of vitamin D binding protein on the surface of cytotrophoblasts isolated from human placentae. Endocrinology 120:1996-2002, 1987.
14. Veldhuis JD, **Nestler JE**, Strauss III JF: The insulin-like growth factor, somatomedin C, modulates low-density lipoprotein metabolism by swine granulosa cells. Endocrinology: 121:340-346, 1987.
15. Clore JN, Brennan JR, Gebhart SSP, Newsome HH, **Nestler JE**, Blackard WG: Prolonged insulin resistance following insulin-induced hypoglycaemia. Diabetologia 30:851-858, 1987.
16. **Nestler JE**: Modulation of aromatase and P450 cholesterol side-chain cleavage enzyme activities of human placental cytotrophoblasts by insulin and insulin-like growth factor I. Endocrinology 121:1845-1852, 1987.

17. **Nestler JE**, Clore JN, Blackard WG: Reduced insulin clearance in normal subjects due to extreme hyperinsulinemia. Am J Med Sci 295:15-22, 1988.
18. **Nestler JE**, Barlascini CO, Clore JN, Blackard WG: Dehydroepiandrosterone reduces serum low-density lipoprotein levels and body fat but does not alter insulin sensitivity in normal men. J Clin Endocrinol Metab 66:57-61, 1988.
19. Roy-Choudhury S, Sen-Majumdar A, Murthy U, Mishra VS, Kliman HJ, **Nestler JE**, Strauss III JF, Das M: Biosynthesis and turnover of a 34-kDa growth factor in human cytotrophoblasts. Eur J Biochem 172:777-783, 1988.
20. **Nestler JE**, Barlascini CO, Clore JN, Blackard WG: Absorption characteristic of breakfast determines insulin sensitivity and carbohydrate tolerance for lunch. Diabetes Care 11:755-760, 1988.
21. Clore JN, **Nestler JE**, Blackard WG: Sleep-associated fall in glucose disposal and hepatic glucose output in normal humans: putative signaling mechanism linking peripheral and hepatic events. Diabetes 38:285-290, 1989.
23. **Nestler JE**, Barlascini CO, Matt DW, Steingold KA, Plymate SR, Clore JN, Blackard WG: Suppression of serum insulin by diazoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 68:1027-1032, 1989.
24. **Nestler JE**: Lack of effect of insulin or insulin-like growth factor I on the steroid sulfatase activity of human placental cytotrophoblasts. Horm Metabol Res 21:258-260, 1989.
25. Clore JN, Glickman PS, Helm ST, **Nestler JE**, Blackard WG: Accelerated decline in hepatic glucose production during fasting in normal women compared with men. Metabolism 38:1103-1107, 1989.
26. **Nestler JE**: Insulin and insulin-like growth factor I stimulate the 3 β -hydroxysteroid dehydrogenase activity of human placental cytotrophoblasts. Endocrinology 125:2127-2133, 1989.
27. **Nestler JE**, Usiskin KS, Barlascini CO, Welty DF, Clore JN, Blackard WG: Suppression of serum dehydroepiandrosterone sulfate levels by insulin: an evaluation of possible mechanisms. J Clin Endocrinol Metab 69:1040-1046, 1989.
28. Clore JN, Helm ST, **Nestler JE**, Blackard WG: Impaired modulation of hepatic glucose output overnight after a 72 hour fast in normal man. J Clin Endocrinol Metab 70:865-868, 1990.
29. Usiskin KS, Butterworth S, Clore JN, Arad Y, Ginsberg HN, Blackard WG, **Nestler JE**: Lack of effect of dehydroepiandrosterone in obese men. Int J Obes 14:457-463, 1990.
30. **Nestler JE**, Barlascini CO, Tetrault GA, Fratkin MJ, Clore JN, Blackard WG: Increased transcapillary escape rate of albumin in nondiabetic men in response to hyperinsulinemia. Diabetes 39:1212-1217, 1990.
31. **Nestler JE**, Singh R, Matt DW, Clore JN, Blackard WG: Suppression of serum insulin by diazoxide does not alter serum testosterone or sex hormone-binding globulin levels in healthy nonobese women. Am J Obstet Gynecol 163:1243-1246, 1990.
32. **Nestler JE**: Insulin-like growth factor II is a potent inhibitor of the aromatase activity of human placental cytotrophoblasts. Endocrinology 127:2064-2070, 1990.
33. Blackard Jr. WG, Clore JN, **Nestler JE**: Failure of a short-term (61 h) fast to enhance the growth hormone response to luteinizing hormone-releasing hormone in normal man. Neuroendocrinology Letters 13:23-26, 1991.
34. Clore JN, Glickman PS, Helm ST, **Nestler JE**, Blackard WG: Evidence for dual control mechanism regulating

- hepatic glucose output in nondiabetic men. Diabetes 40:1033-1040, 1991.
35. Clore JN, Glickman PS, **Nestler JE**, Blackard WG: In vivo evidence for hepatic autoregulation during FFA-stimulated gluconeogenesis in normal humans. Am J Physiol 261:E425-E429, 1991.
 36. **Nestler JE**, Powers LP, Matt DW, Steingold KA, Plymate SR, Rittmaster RS, Clore JN, Blackard WG: A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab 72:83-89, 1991.
 37. **Nestler JE**, Romero G, Huang LC, Zhang C, Lerner J: Insulin mediators are the signal transduction system responsible for insulin's actions on human placental steroidogenesis. Endocrinology 129:2951-2956, 1991.
 38. Clore JN, Post EP, Bailey DJ, **Nestler JE**, Blackard WG: Evidence for increased liver glycogen in patients with non-insulin dependent diabetes mellitus after a 3-day fast. J Clin Endocrinol Metab 74:660-666, 1992.
 39. **Nestler JE**, McClanahan MA, Clore JN, Blackard WG: Insulin inhibits adrenal 17,20-lyase activity in man. J Clin Endocrinol Metab 74:362-367, 1992.
 40. Kauma SW, Walsh SW, **Nestler JE**, Turner TT: Interleukin-1 is induced in the human placenta by endotoxin and isolation procedures for trophoblasts. J Clin Endocrinol Metab 75:951-955, 1992.
 41. Beer NA, Jakubowicz DJ, Beer RM, Arocha IR, **Nestler JE**: Effects of nitrendipine on glucose tolerance and serum insulin and dehydroepiandrosterone sulfate levels in insulin-resistant obese and hypertensive men. J Clin Endocrinol Metab 76:178-183, 1993.
 42. Eich DM, **Nestler JE**, Johnson DE, Dworkin GH, Ko D, Wechsler AS, Hess ML: Inhibition of accelerated coronary atherosclerosis with dehydroepiandrosterone in the heterotopic rabbit model of cardiac transplantation. Circulation 87:261-269, 1993.
 43. **Nestler JE**: Interleukin-1 stimulates the aromatase activity of human placental cytotrophoblasts. Endocrinology 132:566-570, 1993.
 44. Blackard WG, Clore JN, Glickman PS, **Nestler JE**, Kellum JM: Insulin sensitivity of splanchnic and peripheral adipose tissue in vivo in morbidly obese man. Metabolism 42:1195-1200, 1993.
 45. Beer NA, Jakubowicz DJ, Beer RM, **Nestler JE**: The calcium channel blocker amlodipine raises serum dehydroepiandrosterone-sulfate and androstenedione, but lowers serum cortisol, in insulin-resistant obese and hypertensive men. J Clin Endocrinol Metab 76:1464-1469, 1993.
 46. Flores JA, Garmey JC, **Nestler JE**, Veldhuis JD: Sites of inhibition of steroidogenesis by activation of protein kinase-C in ovarian (granulosa) cells. Endocrinology 132:1983-1990, 1993.
 47. **Nestler JE**, Beer NA, Jakubowicz DJ, Beer RM: Effects of a reduction in circulating insulin by metformin on serum dehydroepiandrosterone sulfate in nondiabetic men. J Clin Endocrinol Metab 78:549-554, 1994.
 48. Beer NA, Jakubowicz DJ, Beer RM, **Nestler JE**: Disparate effects of insulin reduction with diltiazem on serum dehydroepiandrosterone sulfate levels in obese, hypertensive men and women. J Clin Endocrinol Metab 79:1077-1081, 1994.
 49. **Nestler JE**, Kahwash Z: Sex-specific action of insulin to acutely increase the metabolic clearance rate of dehydroepiandrosterone in humans. J Clin Invest 94:1484-1489, 1994.
 50. **Nestler JE**, Beer NA, Jakubowicz DJ, Beer RM: Effects of insulin reduction with benfluorex on serum dehydroepiandrosterone (DHEA), DHEA-sulfate, and blood pressure in hypertensive middle-aged and elderly men. J Clin Endocrinol Metab 80:700-706, 1995.

51. Jakubowicz DJ, Beer NA, Beer RM, **Nestler JE**: Disparate effects of weight reduction by diet on serum dehydroepiandrosterone-sulfate levels in obese men and women. J Clin Endocrinol Metab 80:3373-3376, 1995.
52. Jesse RL, Loesser K, Eich DM, Qian YZ, Hess ML, **Nestler JE**: Dehydroepiandrosterone inhibits human platelet aggregation in vitro and in vivo. Ann NY Acad Sci 774:281-290, 1995.
53. Pasquali R, Cantobelli S, Vicennati V, Spinucci G, De lasio R, Mesini P, Boschi S, **Nestler JE**: Nitrendipine treatment in women with polycystic ovary syndrome: evidence for lack of effects of calcium-channel blockers on insulin, androgens and sex hormone-binding globulin. J Clin Endocrinol Metab 80:3346-3350, 1995.
54. Beer NA, Jakubowicz DJ, Matt DW, Beer RM, **Nestler JE**: Dehydroepiandrosterone reduces plasma plasminogen activator inhibitor type 1 and tissue plasminogen activator antigen in men. Am J Med Sci 311:205-210, 1996.
55. **Nestler JE**, Jakubowicz DJ: Decreases in ovarian cytochrome P450c17 α activity and serum free testosterone after reduction of insulin secretion in women with the polycystic ovary syndrome. N Engl J Med 335:617-623, 1996.
56. Jakubowicz DJ, **Nestler JE**. 17 α -Hydroxyprogesterone response to leuprolide and serum androgens in obese women with and without polycystic ovary syndrome after dietary weight loss. J Clin Endocrinol Metab 82:556-560, 1997.
57. Lavallée B, Provost PR, Kahwash Z, **Nestler JE**, Bélanger A: Effect of insulin on plasma levels of dehydroepiandrosterone metabolites in men. Clin Endocrinol (Oxf) 46:93-100, 1997.
58. **Nestler JE**, Jakubowicz DJ. Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17 α activity and serum androgens. J Clin Endocrinol Metab 82:4075-4079, 1997.
59. **Nestler JE**, Jakubowicz DJ, de Vargas AF, Brik C, Quintero N, Medina F: Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. J Clin Endocrinol Metab 83:2001-2005, 1998.
60. **Nestler JE**, Jakubowicz DJ, Evans WS, Pasquali R: Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med 338:1876-1880, 1998.
61. **Nestler JE**, Jakubowicz DJ, Reamer P, Gunn RD, Allan G: Ovulatory and metabolic effects of d-*chiro*-inositol in the polycystic ovary syndrome. N Engl J Med 340:1314-1320, 1999.
62. Barnhart KT, Freeman E, Grisso JA, Rader DJ, Sammel M, Kapoor S, **Nestler JE**: The effect of dehydroepiandrosterone supplementation to symptomatic perimenopausal women on serum endocrine profiles, lipid parameters, and health-related quality of life. J Clin Endocrinol Metab 84:3896-3902, 1999.
63. Jakubowicz DJ, Seppälä M, Jakubowicz S, Rodriguez-Armas O, Rivas-Santiago A, Koistinen H, Koistinen R, **Nestler JE**: Insulin reduction with metformin increases luteal phase serum glycodelin and insulin-like growth factor binding protein 1 concentrations and enhances uterine vascularity and blood flow in the polycystic ovary syndrome. J Clin Endocrinol Metab 86:1126-1133, 2001.
64. Vandermolen DT, Ratts VS, Evans WS, Stovall DW, Kauma SW, **Nestler JE**: Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. Fertil Steril 75:310-315, 2001.
65. Peppard HR, Marfori J, Iuorno MJ, **Nestler JE**: Prevalence of polycystic ovary syndrome among premenopausal women with type 2 diabetes mellitus. Diabetes Care 24:1050-1052, 2001.

66. Luorno MJ, Jakubowicz DJ, Baillargeon JP, Dillon P, Gunn RD, Allan G, **Nestler JE**: Effects of D-*chiro*-inositol in lean women with the polycystic ovary syndrome. Endocrine Practice 8:417-423, 2002.
67. Jakubowicz DJ, Luorno MJ, Jakubowicz S, Roberts KA, **Nestler JE**: Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. J Clin Endocrinol Metab 87:524-529, 2002.
68. **Nestler JE**, Whitfield JB, Williams TY, Zhu G, Condon J, Kirk KM, Heath AC, Montgomery GW, Martin NG: Genetics of serum dehydroepiandrosterone sulfate (DHEA-S) and its relationship to insulin in a population-based cohort of twin subjects. J Clin Endocrinol Metab 87:682-686, 2002.
69. Whitfield JB, Zhu Gu, **Nestler JE**, Heath AC, Martin NC: Genetic covariation between serum gamma glutamyltransferase activity and cardiovascular risk factors. Clin Chem 48:1426-1431, 2002.
70. Baillargeon JP, Luorno MJ, Jakubowicz DJ, Apridonidze T, He N, **Nestler JE**: Metformin therapy increases insulin-stimulated release of a D-*chiro*-inositol-containing inositolphosphoglycan mediator in women with polycystic ovary syndrome. J Clin Endocrinol Metab 89:242-249, 2004.
71. Baillargeon JP, Jakubowicz DJ, Luorno MJ, Jakubowicz S, **Nestler JE**: Effects of metformin and rosiglitazone, alone and in combination, in non-obese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertil Steril 82:893-902, 2004.
72. Jakubowicz DJ, Essah PA, Seppala M, Jakubowicz S, Koistinen R, **Nestler JE**: Reduced serum glycodelin and insulin-like growth factor-binding protein-1 in women with polycystic ovary syndrome during first trimester of pregnancy. J Clin Endocrinol Metab 89:833-839, 2004.
73. Fonesca VA, Kelley DE, Cefalu W, Baron MA, Purkayastha D, **Nestler JE**, Hsia S, Gerich JE: Hypoglycemic potential of nateglinide versus glyburide in patients with Type 2 diabetes mellitus. Metabolism 53:1331-1335, 2004.
74. Baillargeon JP, McClish DK, Essah PA, **Nestler JE**: Association between the current use of low-dose oral contraceptives and cardiovascular disease: a meta-analysis. J Clin Endocrinol Metab, in press (2005).
75. Myers ER, Silva SG, Hafley G, Kunselman AR, **Nestler JE**, Legro RS: Estimating live birth rates after ovulation induction in polycystic ovary syndrome: Sample size calculations for the pregnancy in polycystic ovary syndrome (PPCOS) trial. Controlled Clinical Trials, in press (2005).
76. Apridonidze T, Essah PA, Luorno MJ, **Nestler JE**: Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 90:1929-1935, 2005.
77. Apridonidze T, Essah PA, Luorno MJ, **Nestler JE**: Effects of short-term and long-term metformin treatment on menstrual cyclicity in women with polycystic ovary syndrome. (Submitted).
78. Baillargeon JP, Diamanti-Kandarakis E, Ostlund RE, Apridonidze T, Luorno MJ, **Nestler JE**: D-*chiro*-inositol clearance, insulin-stimulated release of D-*chiro*-inositol-containing inositolphosphoglycan, and insulin sensitivity in women with polycystic ovary syndrome. (Submitted)

Books

Androgen Excess Disorders in Women, edited by Azziz R, **Nestler JE** and Dewailly D, Lippincott-Raven Press, Philadelphia, 831 pages, 1997.

Reviews, Editorials and Book Chapters

1. **Nestler JE**: Grand rounds: idiopathic hemochromatosis. Va Med 109:836-839, 1982.

2. **Nestler JE**, Bamberger M, Rothblat GH, Strauss III JF: Preferential utilization of the free cholesterol moiety of high density lipoprotein by cultured rat granulosa cells. In: Lipoprotein and cholesterol metabolism in steroidogenic tissues (Menon KMJ and Strauss III JF, eds.), George F. Stickley Company, Philadelphia, PA, pp. 135-139, 1985.
3. Strauss III JF, Paavola LG, **Nestler JE**, Soto EA, Silavin SL: Lipoprotein cholesterol uptake and metabolism in ovarian cells. In: Proceedings of the fifth ovarian workshop (Ryan RJ and Toft DO, eds.), Ovarian Workshops, Champaign, ILL, pp.275-302, 1985.
4. Paavola LG, Strauss III JF, Boyd CO, **Nestler JE**: Cellular uptake of high and low density lipoproteins by rat ovarian cells. In: Lipoprotein and cholesterol metabolism in steroidogenic tissues (Menon KMJ and Strauss III JF, eds.), George F. Stickley Company, Philadelphia, PA, pp. 171-186, 1985.
5. **Nestler JE**, Attie MA: Idiopathic edema. Va Med 113:402-406, 1986.
6. **Nestler JE**, Barlascini CO, Clore JN, Blackard WG: Dehydroepiandrosterone: effects on insulin sensitivity, serum lipid levels, and body composition in normal men. In: Hormones, thermogenesis, and obesity: proceedings of the eighteenth Steenbock symposium. (Lardy HA and Stratman F, eds.), Elsevier Science Publishers B.V., NY, pp. 405-414, 1988.
7. Blackard WG, Barlascini CO, Clore JN, **Nestler JE**: Morning insulin requirements: critique of dawn and meal phenomena. Diabetes 38:273-277, 1989.
8. **Nestler JE**: Evaluation and treatment of the hirsute woman. Va Med 116:310-315, 1989.
9. **Nestler JE**, Clore JN, Blackard WG: The central role of obesity (hyperinsulinemia) in the pathogenesis of the polycystic ovary syndrome. Am J Obstet Gynecol 161:1095-1097, 1989.
10. **Nestler JE**: Insulin and insulin-like growth factor I as modulators of human placental steroidogenesis. In: Progress in perinatal medicine. VI. (Gati I, ed), KOPINT-DATORG Publishers, Budapest, pp. 175-182, 1989.
11. **Nestler JE**, Takagi K, Strauss III JF: Lipoprotein and cholesterol metabolism in cells that synthesize steroid hormones. In: Advances in cholesterol research (Esfahani M and Swaney JB, eds.), Telford Press, Caldwell, NJ, pp. 133-169, 1990.
12. **Nestler JE**, Clore JN, Blackard WG: Regulation of dehydroepiandrosterone metabolism by insulin, and the metabolic effects of dehydroepiandrosterone in man. In: The biologic role of dehydroepiandrosterone (DHEA) (Kalimi M and Regelson W, eds.), Walter de Gruyter & Co., Berlin, pp. 189-205, 1990.
13. **Nestler JE**, Clore JN, Blackard WG: Metabolism and actions of dehydroepiandrosterone in humans. J Steroid Biochem Molec Biol 40:599-605, 1991.
14. **Nestler JE**, Strauss III JF: Insulin as an effector of human ovarian and adrenal steroid metabolism. Endocrinol Metab Clin North Am 20(4):807-823, 1991.
15. **Nestler JE**, Clore JN, Blackard WG: Dehydroepiandrosterone: the "missing link" between hyperinsulinemia and atherosclerosis? FASEB J 6:3073-3075, 1992.
16. **Nestler JE**, Clore JN, Blackard WG: Effects of insulin on steroidogenesis in vivo. In: Polycystic Ovary Syndrome (Current Issues in Endocrinology and Metabolism), (Dunaif A, Givens JR, Haseltine FP, Merriam GR, eds.), Blackwell Scientific Publications, Cambridge, MA, pp. 265-278, 1992.
17. **Nestler JE**, McClanahan MA: Diabetes and adrenal disease. Baillière's Clinical Endocrinology and Metabolism 6(4):829-847, 1992.
18. **Nestler JE**: Regulation of the aromatase activity of human placental cytotrophoblasts by insulin,

- insulin-like growth factor-I, and -II. J Steroid Biochem Molec Biol 44:449-457, 1993.
19. **Nestler JE:** Editorial: Sex hormone-binding globulin: a marker for hyperinsulinemia and/or insulin resistance? J Clin Endocrinol Metab 76:272-273, 1993.
 20. **Nestler JE:** Insulin and adrenal androgens. Sem Reprod Endocrinol 12:1-5, 1994.
 21. **Nestler JE:** Assessment of insulin resistance. Science & Medicine 1:58-67, 1994.
 22. **Nestler JE:** Role of obesity and insulin in the development of anovulation. In: Ovulation induction: basic science and clinical advances (Filicori M and Flamigni C, eds.), Elsevier, Amsterdam, pp. 103-114, 1994.
 23. Blackard WG, **Nestler JE**, Clore JN: Clinical manifestations and significance of insulin resistance. Pennington Center Nutrition Series. Volume 4: Nutrition, endocrinology, and disease (Bray GA and Ryan DH, eds.), Louisiana State University Press, Baton Rouge, pp. 177-188, 1995.
 24. **Nestler JE:** Dehydroepiandrosterone (DHEA), obesity, and obesity-related atherosclerosis. Progress in obesity Research 94 (Angel A ,ed.), John Libbey & Co., London, pp. 685-689, 1995.
 25. **Nestler JE:** Are there sex-specific effects of insulin on human dehydroepiandrosterone metabolism?. Sem Reprod Endocrinol 13:282-287, 1995.
 26. **Nestler JE:** Regulation of human dehydroepiandrosterone metabolism by insulin. Ann NY Acad Sci 774:73-81, 1995.
 27. **Nestler JE:** DHEA: A coming of age. Ann NY Acad Sci 774:ix-xi, 1995.
 28. **Nestler JE:** Advances in understanding the regulation and biologic actions of dehydroepiandrosterone. Curr Opin Endocrinol Diabetes 3:202-211, 1996.
 29. **Nestler JE:** Insulin regulation of human ovarian androgens. Hum Reprod 12:53-62, 1997.
 30. **Nestler JE:** Insulin and ovarian androgen excess. In: Androgen Excess Disorders in Women (Azziz R, **Nestler JE**, Dewailly D, eds.), Lippincott-Raven Press, Philadelphia, pp. 473-484, 1997.
 31. **Nestler JE:** Suppression of ovarian androgen biosynthesis: reduction of circulating insulin. In: Androgen Excess Disorders in Women (Azziz R, **Nestler JE**, Dewailly D, eds.), Lippincott-Raven Press, Philadelphia, pp. 727-736, 1997.
 32. **Nestler JE.** Role of hyperinsulinemia in the pathogenesis of the polycystic ovary syndrome, and its clinical implications. Sem Reprod Endocrinol 15:111-122, 1997.
 33. **Nestler JE.** Dehydroepiandrosterone: fountain of youth or snake oil? The Endocrinologist 7:423-428, 1997.
 34. **Nestler JE:** Inositolphosphoglycans (IPGs) as mediators of insulin's steroidogenic actions. Journal of Basic and Clinical Physiology & Pharmacology 9:197-204, 1998.
 35. Pahle N, **Nestler JE:** DHEA (Dehydroepiandrosterone). In: Encyclopedia of Reproduction (Knobil E and Strauss J, eds), Academic Press, Vol 1, pp. 858-862, 1999.
 36. Iuorno MJ, **Nestler JE:** The polycystic ovary syndrome: treatment with insulin sensitizing agents. Diabetes, Obesity & Metabolism 1(3):127-136, 1999.
 37. **Nestler JE:** Polycystic ovary syndrome: a disorder for the generalist. Fertil Steril 70:811-812, 1998.
 38. **Nestler JE:** Insulin resistance: effects on sex hormones and ovulation in the polycystic ovary syndrome. In:

Insulin Resistance: The Metabolic Syndrome X (Reaven G and Laws A, eds.), Chapter 19, Humana Press, Totowa, NJ, pp. 347-366, 1999.

39. **Nestler JE:** Obesity, insulin, sex steroids and ovulation. Int J Obesity Relat Metab Disord 24:S71-S73, 2000.
40. **Nestler JE,** Jakubowicz DJ, Luorno MJ: Role of inositolphosphoglycan mediators of insulin action in the polycystic ovary syndrome. J Pediatr Endocrinol Metab 13:1295-1298, 2000.
41. **Nestler JE:** Insulin resistance and the polycystic ovary syndrome: recent advances. Curr Opin Endocrinol Diabetes 7:345-349, 2000.
42. Luorno MJ, **Nestler JE:** Insulin-lowering drugs in polycystic ovary syndrome. Obstet Gynecol Clin North Am 28 (1):153-164, 2001.
43. **Nestler JE,** Stovall D, Akhter N, Luorno MJ, Jakubowicz DJ: Strategies for the use of insulin-sensitizing drugs to treat infertility in women with polycystic ovary syndrome. Fertil Steril 77:209-215, 2002.
44. Baillargeon JP, Luorno MJ, **Nestler JE:** Comparison of metformin and thiazolidinediones in the treatment of polycystic ovary syndrome. Curr Opin Endocrinol Diabetes 9:303-311, 2002.
45. **Nestler JE:** Should patients with polycystic ovary syndrome be treated with metformin? An enthusiastic endorsement. Hum Reprod 17:1950-1953, 2002.
46. Baillargeon JP, Luorno MJ, **Nestler JE:** Insulin sensitizers for polycystic ovary syndrome. Clinical Obstetrics and Gynecology 46(2):325-340, 2003.
47. Diamanti-Kandarakis E, Baillargeon JP, Luorno MJ, Jakubowicz DJ, **Nestler JE:** A modern medical quandary: Polycystic ovary syndrome, insulin resistance, and oral contraceptive pills. J Clin Endocrinol Metab 88:1927-1931, 2003.
48. Luorno MJ, **Nestler JE:** Insulin-lowering drugs in polycystic ovary syndrome. Infert Reprod Med Clin N Am 14:639-651, 2003.
49. **Nestler JE:** Insulin resistance syndrome and polycystic ovary syndrome. Endocrine Practice 9(suppl 2):86-89, 2003.
50. Luorno MJ, Baillargeon JP, **Nestler JE:** Polycystic ovary syndrome. In: Primary Care for Women (Leppert PC and Peipert JF, eds.), 2nd Edition, Lippincott, Williams & Wilkins, Philadelphia, pp. 262-266, 2004.
51. Cheang KI, **Nestler JE:** Should insulin-sensitizing drugs be used in the treatment of polycystic ovary syndrome? Reproductive BioMedicine Online (www.rbmonline.com/Article/1229) 8:440-447, 2004.
52. Cheang KI, Essah PA, **Nestler JE:** A paradox: the roles of inositolphosphoglycans in mediating insulin sensitivity and hyperandrogenism in the polycystic ovary syndrome. Hormones 3:244-251, 2004.
53. Essah PA, Cheang KI, **Nestler JE:** The pathophysiology of miscarriage in women with polycystic ovary syndrome. Review and proposed hypothesis of mechanisms involved. Hormones 3:221-227, 2004.

Video Programs

Nestler JE: Physiology and pathophysiology of diabetes. In: Certified diabetes educator review, Nursing Tutorial & Consulting Services, Annandale, VA, 1991

Abstracts

1. **Nestler JE**, Gebhart SSP, Blackard WG: Failure of mid-nocturnal insulin infusion to suppress the increased insulin need for breakfast in insulin-dependent diabetics. Clin Res 31:883A, 1983.
2. **Nestler JE**, Bamberger M, Rothblat GH, Strauss III JF: Metabolism of HDL reconstituted with 3H-cholesteryl ester and 14C-free cholesterol in the rat, with special reference to the ovary. J Steroid Biochem 20:1519 (Abstract G14), 1984.
3. **Nestler JE**, Chacko GK, Strauss III JF: Modification of tyrosine residues of human high density lipoproteins (HDL) with tetranitromethane prevents high-affinity binding of the particles, but does not alter their capacity to stimulate steroidogenesis. Clin Res 33:441A, 1985.
4. Kliman HJ, **Nestler JE**, Sermasi E, Strauss III JF: Electron microscopic, immunocytochemical and biochemical characterization of isolated trophoblasts from human term placentae. Fed Proc 44:420 (Abstract 56), 1985.
5. **Nestler JE**, Lange E, McLeod JF, Kliman HJ, Strauss III JF, Haddad, Jr., JG: Detection of vitamin D binding protein (DBP) in/on human cytotrophoblasts. 1985 Program and Abstracts of the 7th Annual Scientific Meeting of the American Society for Bone and Mineral Research, Abstract 266.
6. Kliman HJ, **Nestler JE**, Sanger JM, Strauss III JF: In vitro differentiation of purified human cytotrophoblasts. J Cell Biol 101:342a (Abstract 1294), 1985.
7. **Nestler JE**, Clore JN, Poynor WJ, Blackard WG: Reduced clearance of insulin due to marked hyperinsulinemia. Clin Res 34:224A, 1986.
8. **Nestler JE**, Clore JN, Strauss III JF, Blackard WG: Effects of extreme hyperinsulinemia on plasma steroids. Clin Res 34:550A, 1986.
9. Roy-Choudhury S, Sen-Majumdar A, Murthy U, Kliman H, Nestler J, Strauss J, Das M: Biosynthetic pathway of a new trophoblast derived growth factor from human placenta. Fed Proc 45:1716 (Abstract 1370), 1986.
10. Veldhuis JD, **Nestler JE**, Strauss III JF: The insulin-like growth factor, somatomedin C, augments the disposal of low density lipoprotein-borne cholesterol by cultured swine granulosa cells. Program and Abstracts of the 1986 Sixth Biennial Ovarian Workshop.
11. Clore JN, Brennan JR, Gebhart SP, Newsome HH, **Nestler JE**, Blackard WG: Prolonged insulin resistance following insulin-induced hypoglycaemia. Diabetologia 29:528A (Abstract 97), 1987.
12. **Nestler JE**, Clore JN, Blackard Jr. WG, Blackard WG: Absorption characteristics of foodstuffs influence the increased insulin requirement for breakfast in Type I diabetic patients. Clin Res 35:24A, 1987.
13. **Nestler JE**: Insulin suppresses aromatization of androgens by human placental cytotrophoblasts. Clin Res 35:24A, 1987.
14. **Nestler JE**, Clore JN, Barlascini CO, Blackard WG: Insulin, insulin sensitivity, and DHEA-S. Presented at the Clinical Research Center Program Director's Conference, Williamsburg, VA, April 1987.
15. **Nestler JE**: Insulin suppresses aromatase activity of human placental cytotrophoblasts, but does not affect P450 side-chain cleavage enzyme activity. First European Congress of Endocrinology, Abstract 2-128, p.35, 1987.
16. **Nestler JE**, Barlascini CO, Clore JN, Blackard WG: Prolonging absorption of breakfast meal enhances insulin sensitivity for lunch. Diabetes (Supplement 1) 37:108A (Abstract 432), 1988.
17. **Nestler JE**, Barlascini CO, Matt DW, Steingold KA, Plymate SR, Clore JN, Blackard WG: Suppression of insulin by diazoxide raises serum sex hormone-binding globulin (SHBG) levels in obese women with

polycystic ovary disease (PCO). Program and Abstracts of the 70th Annual Scientific Meeting of The Endocrine Society, Abstract 194, p. 69, 1988.

18. **Nestler JE**, Barlascini CO, Clore JN, Blackard WG: Effects of dehydroepiandrosterone on body composition, lipids, and insulin sensitivity in men. Program and Abstracts of the 18th Steenbock Symposium, University of Wisconsin-Madison, June 1988.
19. Clore JN, Glickman PS, Helm ST, **Nestler JE**, Blackard WG: Accelerated decline in hepatic glucose production during fasting in normal women compared to men. Clin Res 37:21A, 1989.
20. **Nestler JE**, Barlascini CO, Clore JN, Blackard WG, Ginsberg HN, Arad Y: Effects of dehydroepiandrosterone (DHEA) on serum apolipoprotein B (apoB) levels and low-density lipoprotein (LDL) particle size in normal men. Clin Res 37:22A, 1989.
21. **Nestler JE**, Usiskin KS, Barlascini CO, Clore JN, Blackard WG: Hyperinsulinemia reduces serum levels of both dehydroepiandrosterone (DHEA) and dehydroepiandrosterone sulfate (DHEA-S) in man. Clin Res 37:22A, 1989.
22. **Nestler JE**, Barlascini CO, Usiskin KS, Clore JN, Blackard WG: Effects of dehydroepiandrosterone (DHEA) in man. Program and Abstracts of the Symposium Pharmaco-Clinique Roussel Uclaf NE 9: "Dehydroepiandrosterone revisited," pp. 25-26, 1989.
23. Clore JN, Helm ST, **Nestler JE**, Blackard WG: Evidence that suppressed nocturnal glucose appearance (Ra) is due to reduced lipolysis. Diabetes 38(Suppl 2):221A (Abstract 841), 1989.
24. **Nestler JE**: Insulin and insulin-like growth factor I as modulators of human placental steroidogenesis. Program of the 6th international symposium on "Progress in perinatal medicine", Budapest, September 28-30, 1989, pp. 101-102.
25. Eich DM, Johnson DE, **Nestler JE**, Daijin K, Hess ML, Wechsler AS: Inhibition of cardiac allograft atherosclerosis by dehydroepiandrosterone. Clin Res 38:2A, 1990.
26. Clore JN, Glickman PS, **Nestler JE**, Blackard WG: Increased free fatty acids stimulate the Cori cycle but do not alter the first substrate (glucose) cycle in normal man. Clin Res 38:16A, 1990.
27. **Nestler JE**, Barlascini CO, Tetrault GA, Fratkin MJ, Clore JN, Blackard WG: Hyperinsulinemia increases the transcapillary escape rate (TER) of albumin in normal men. Clin Res 38:33A, 1990.
28. Clore JN, Glickman PS, Helm ST, **Nestler JE**, Blackard WG: Free fatty acid induced gluconeogenesis results in a compensatory decrease in glycogenolysis in normal man. Diabetes 39(Suppl 1):26A (Abstract 103), 1990.
29. **Nestler JE**: Dehydroepiandrosterone (DHEA) actions and metabolism in man. J Steroid Biochem 36(Suppl):9S (Abstract 20), 1990.
30. **Nestler JE**, Powers LJ, Matt DW, Steingold KA, Plymate SR, Clore JN, Blackard WG: Insulin directly suppresses serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. Program and Abstracts of the 72th Annual Scientific Meeting of The Endocrine Society, Abstract 713, p. 203, 1990.
31. McClanahan MA, Clore JN, Blackard WG, **Nestler JE**: Insulin inhibits adrenal 17,20-lyase activity. Clin Res 38:979A, 1990.
32. Blackard WG, Clore JN, Glickman PS, **Nestler JE**, Kellum J: Central obesity - a marker for insulin resistance. Diabetes 40(Suppl 1):235A (Abstract 937), 1991.

33. Jesse R, **Nestler J**, Eich D, Hess M: Dehydroepiandrosterone in vivo and in vitro inhibits platelet aggregation. J Am Coll Cardiol 17(Suppl A):376A, 1991.
34. McClanahan MA, Clore JN, Blackard WG, **Nestler JE**: Insulin selectively inhibits adrenal 17,20-lyase activity in man. Program and Abstracts of the 73rd Annual Meeting of The Endocrine Society, Abstract 807, p. 232, 1991.
35. **Nestler JE**, Huang LC, Zhang C, Lerner J: Insulin mediators mimic insulin's actions on human placental steroidogenesis. Program and Abstracts of the 73rd Annual Meeting of The Endocrine Society, Abstract 1759, p. 470, 1991.
36. Tolman DE, Loesser KE, Wechsler AS, **Nestler JE**, Johnson DE, Hess ML: Ultrastructural evidence for dehydroepiandrosterone (DHEA) delay of endothelial injury in heterotopic transplanted rabbit aorta. Circulation 86(4):I-36 (Abstract 140), 1992.
37. **Nestler JE**: Interleukin-1 stimulates the aromatase activity of human placental cytotrophoblasts. Clin Res 40:812A, 1992.
38. Tolman DE, Johnson DE, **Nestler JE**, Allen C, Wechsler AS, Hess ML: Dietary dehydroepiandrosterone (DHEA) inhibits graft arteriosclerosis in rabbit heterotopic cardiac allografts. J Am Coll Cardiol 21(Suppl A):142A (Abstract 878-12), 1993.
39. Tolman DE, Johnson DE, **Nestler JE**, Hoang S, Wechsler AS, Hess ML: Dehydroepiandrosterone (DHEA) inhibits cardiac graft arteriosclerosis by attenuating chronic humoral rejection. J Heart Lung Transplant 12(1):S94, 1993.
40. Beer NA, Jakubowicz DJ, Beer RM, **Nestler JE**: The calcium channel blocker amlodipine raises serum dehydroepiandrosterone-sulfate and androstenedione, but lowers serum cortisol, in insulin-resistant obese and hypertensive men. Clin Res 41:356A, 1993.
41. **Nestler JE**: Central role of insulin in the pathogenesis of the polycystic ovary syndrome. Program and Abstracts of the 75th Annual Meeting of The Endocrine Society, p. 19, 1993.
42. Kahwash Z, O'Brien R, **Nestler JE**: Insulin acutely increases the metabolic clearance rate (MCR) of dehydroepiandrosterone (DHEA) in men. Clin Res 41:800A, 1993.
43. Kahwash Z, **Nestler JE**: Insulin increases the metabolic clearance rate (MCR) of dehydroepiandrosterone (DHEA) in men but not in women. Abstracts of the 76th Annual Meeting of The Endocrine Society, p. 530 (Abstract 1319), 1994.
44. **Nestler JE**: Dehydroepiandrosterone, obesity, and obesity-related atherosclerosis. Int J Obes 18(Suppl 2):87 (Abstract O340), 1994.
45. Beer NA, Jakubowicz DJ, Beer RM, **Nestler JE**: Effect of oral dehydroepiandrosterone administration on plasminogen activator inhibitor type 1 levels in middle-aged men. Circulation 90(4):I-179 (Abstract 963), 1994.
46. Matthews BJ, Loesser KE, **Nestler JE**, Jesse RL: Myointimal proliferation following vascular injury is attenuated by dehydroepiandrosterone. J Invest Med 43(Suppl 2):271A, 1995.
47. Jakubowicz DJ, Beer NA, Beer RM, **Nestler JE**: Disparate effects of weight reduction by diet on serum dehydroepiandrosterone-sulfate levels in obese men and women. Abstracts of the 76th Annual Meeting of The Endocrine Society, p. 481 (Abstract P3-49), 1995.
48. **Nestler JE**, Beer NA, Jakubowicz DJ, Matt DW, Beer RM: Oral dehydroepiandrosterone (DHEA) administration enhances fibrinolysis in men. Abstracts of the 77th Annual Meeting of The Endocrine Society,

p. 60 (Abstract OR10-5), 1995.

49. Jakubowicz DJ, **Nestler JE**: Effects of metformin on circulating insulin and P450_{17α} activity in women with the polycystic ovary syndrome (PCOS). Abstracts of the Ferring conference on "The Ovary: Regulation, Dysfunction and Treatment", Marco Island, FL, January 25-27, 1996.
50. **Nestler JE**, Jakubowicz DJ: Evidence that hyperinsulinemia induces dysregulation of P450c17α and increases serum free testosterone in the polycystic ovary syndrome (PCOS). Program & Abstracts of the 10th International Congress of Endocrinology, p. 93 (Abstract OR26-3), 1996.
51. **Nestler JE**. DHEA and prevention of heart disease. J Am Col Nutr 16(5):494 (Abstract 89), 1997.
52. **Nestler JE**, Jakubowicz DJ, Falcon de Vargas A, Brik C, Quintero N, Medina F: In the polycystic ovary syndrome insulin stimulates human thecal testosterone production via its own receptor by using inositolglycan mediators as the signal transduction system. Program and Abstracts of the 79th Annual Scientific Meeting of The Endocrine Society, p. 389 (Abstract P2-418), 1997.
53. **Nestler JE**, Jakubowicz DJ, Evans WS, Pasquali R: Metformin increases spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. Program of the 53rd Annual Meeting of the American Society for Reproductive Medicine, p.75, 1997.
54. Barnhart KT, Rader D, Freeman E, Kapoor K, Smith P, **Nestler JE**: The effect of DHEA replacement on the endocrine and lipid profiles of perimenopausal women. Program Supplement to the 53rd Annual Meeting of the American Society for Reproductive Medicine, p. S41 (Abstract O-081), 1997.
55. Carr ME, Carr SL, Monge-Meberg P, Williams TY, **Nestler JE**: Effects of dehydroepiandrosterone (DHEA) on platelet function, fibrinolysis and clot structure. Blood 90 (Suppl 1):Abstract 3124, 1997.
56. **Nestler JE**, Jakubowicz DJ, Reamer P, Gunn RD, Allan G: Effects of D-*chiro*-inositol (INS-1) on insulin, glucose and spontaneous ovulation in obese women with polycystic ovary syndrome (PCOS). (presented at the 1998 annual scientific meeting of the American Diabetes Association).
57. **Nestler JE**, Jakubowicz, DJ, Evans WS, Pasquali R: Metformin increases spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. (presented at the 80th annual scientific meeting of The Endocrine Society).
58. Freeman EW, Barnhart KT, **Nestler JE**, Garcia B: Effects of DHEA administration on perimenopausal symptoms. (submitted to June 1998 New Clinical Drug Evaluation Unit, NIMH, conference).
59. **Nestler JE**: Dehydroepiandrosterone: fountain of youth or snake oil? (Presented at the 80th annual scientific meeting of The Endocrine Society).
60. Luorno MJ, Williams T, Gennings C, Bear H, Desch C, **Nestler JE**: Assessment of insulin sensitivity in women with breast cancer. Program and Abstracts of the 81st Annual Scientific Meeting of The Endocrine Society, p. 474 (Abstract P3-170), 1999.
61. Vandermolen DT, Ratts VS, Evans WS, **Nestler JE**: Metformin increases the ovulatory response to clomiphene citrate (CC) in patients resistant to CC alone. Abstracts of the 55th annual scientific meeting of the American Society for Reproductive Medicine, p. S171 (Abstract P-255), 1999.
62. Luorno MJ, Jakubowicz, DJ, Dillon P, Eisner JR, Gunn, RD, Allan G, **Nestler JE**: Lean women with the polycystic ovary syndrome: d-*chiro*-inositol reduces serum insulin and androgens, improves ovulation, and beneficially affects syndrome X by decreasing blood pressure and serum triglycerides. Program and Abstracts of the 82nd Annual Scientific Meeting of The Endocrine Society, p. 400 (Abstract 1653), 2000.
63. Jakubowicz DJ, Seppala M, Jakubowicz S, Rodriguez-Armas O, Rivas-Santiago A, Koistinen H, Koistinen R,

- Nestler JE:** Polycystic ovary syndrome and early pregnancy loss: metformin treatment increases luteal-phase serum progesterone, glycodelin and insulin-like growth factor binding protein-1 concentrations after clomiphene-induced ovulation in the polycystic ovary syndrome. Program and Abstracts of the 82nd Annual Scientific Meeting of The Endocrine Society, p. 405 (Abstract 1674), 2000.
64. Vandermolen DT, Ratts VS, Evans WS, Stovall DW, Kauma SW, **Nestler JE:** Metformin increases the ovulatory response to clomiphene citrate (CC) in patients resistant to CC alone. Program and Abstracts of the 82nd Annual Scientific Meeting of The Endocrine Society, p. 563 (Abstract 2332), 2000.
 65. Jakubowicz DJ, Luorno MJ, Jakubowicz S, Roberts KA, **Nestler JE:** Metformin reduces early pregnancy loss in polycystic ovary syndrome. Program and Abstracts of the 83rd Annual Scientific Meeting of The Endocrine Society, p. 384 (Abstract P2-427), 2001.
 66. **Nestler JE,** Gunn R, Bates S, Jacobson W, Rogol A for the PCOS Study Group: D-*chiro*-inositol (INS-1) enhances ovulatory rate in hyperandrogenic, oligomenorrheic women with the polycystic ovary syndrome (PCOS). Fertil Steril 76 (3S): S110-S111 (Abstract O-293), 2001.
 67. Luorno MJ, Evans, WS, Boyd DG, Johnson ML, **Nestler JE:** Synchrony between LH and leptin pulsatile secretion in women with polycystic ovary syndrome. Program and Abstracts of the 84th Annual Scientific Meeting of The Endocrine Society, p. 463 (Abstract P2-613), 2002.
 68. Baillargeon JP, Jakubowicz DJ, Luorno MJ, Jakubowicz S, **Nestler JE:** Effects of metformin and rosiglitazone, alone and in combination, in lean women with polycystic ovary syndrome and normal indices of insulin sensitivity. Program and Abstracts of the 84th Annual Scientific Meeting of The Endocrine Society, p. 78 (Abstract OR10-1), 2002.
 69. Baillargeon JP, Luorno MJ, Jakubowicz DJ, **Nestler JE:** Metformin therapy increases insulin stimulated release of the D-*chiro*-inositol-containing inositolphosphoglycan (DCI-IPG) mediator in women with polycystic ovary syndrome. Program and Abstracts of the 84th Annual Scientific Meeting of The Endocrine Society, p. 469 (Abstract P2-636), 2002.
 70. Baillargeon JP, Dimanti-Kanadaraki E, Ostlund RE, Apridonidze T, Luorno MJ, **Nestler JE:** D-*chiro*-inositol urinary fractional excretion, insulin stimulated release of the D-*chiro*-inositol-containing inositolphosphoglycan insulin mediator and insulin sensitivity in women with polycystic ovary syndrome. Program and Abstracts of the 85th Annual Scientific Meeting of The Endocrine Society, p. 83 (Abstract OR18-2), 2003.
 71. Essah PA, Jakubowicz DJ, Seppala M, Jakubowicz S, Koistinen R, **Nestler JE:** Reduced serum glycodelin and insulin-like growth factor binding protein-1 in women with polycystic ovary syndrome during the first trimester of pregnancy. Program and Abstracts of the 85th Annual Scientific Meeting of The Endocrine Society, p. 119 (Abstract OR43-1), 2003.
 72. Baillargeon JP, Diamanti-Kandarakis E, Ostlund RE, Apridonidze T, Luorno MJ, Nestler JE: D-*chiro*-inositol clearance, insulin stimulated release of D-*chiro*-inositol-containing inositolphosphoglycan and insulin sensitivity in women with polycystic ovary syndrome. Program and Abstracts of the 86th Annual Scientific Meeting of The Endocrine Society, p. 118 (Abstract OR31-2), 2004.
 73. Baillargeon JP, McClish DK, Essah PA, Nestler JE: Association between the current use of low-dose oral contraceptives and cardiovascular disease: A meta-analysis. Program and Abstracts of the 86th Annual Scientific Meeting of The Endocrine Society, p. 292 (Abstract P1-549), 2004.
 74. Luorno MJ, Evans WS, Boyd DG, Johnson ML, Nestler JE: Leptin secretory burst parameters correlate with BMI in normal women but not in women with PCOS. Program and Abstracts of the 86th Annual Scientific Meeting of The Endocrine Society, p. 289 (Abstract P1-536), 2004.
 75. Luorno MJ, Boyd DG, Islam LZ, Veldhuis PP, Johnson ML, Nestler JE, Evans WS. Leptin diurnal amplitude correlates with BMI in both normal and PCOS women. Program and Abstracts of the 87th Annual Scientific Meeting of The Endocrine Society, p. 289 (Abstract P1-536), 2004.

Meeting of The Endocrine Society, 2005 (in press).